These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 12200795)

  • 21. Relationship of antihypertensive effect of enalapril to serum MK-422 levels and angiotensin converting enzyme inhibition.
    Johnston CI; Jackson B; McGrath B; Matthews G; Arnolda L
    J Hypertens Suppl; 1983 Oct; 1(1):71-5. PubMed ID: 6100611
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Antihypertensive therapy in the presence of proteinuria.
    Sarafidis PA; Khosla N; Bakris GL
    Am J Kidney Dis; 2007 Jan; 49(1):12-26. PubMed ID: 17185142
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Hypotensive effectiveness of therapy combined enalapril and nitrendipine and influence on the quality of life].
    Bryl W; Cymerys M; Kujawska-Luczak M; Pupek-Musialik D
    Pol Merkur Lekarski; 2005 Mar; 18(105):287-90. PubMed ID: 15997634
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Is the antiproteinuric response to inhibition of the renin-angiotensin system less effective during the night?
    Buter H; Hemmelder MH; van Paassen P; Navis G; de Zeeuw D; de Jong PE
    Nephrol Dial Transplant; 1997; 12 Suppl 2():53-6. PubMed ID: 9269701
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [PRIVILEGIYA (Privilege) study - Prestarium in the treatment of arterial hypertension: antihypertensive effectiveness and safety in comparison with enalapril].
    Karpov IuA; Deev AD;
    Kardiologiia; 2007; 47(7):35-40. PubMed ID: 18260893
    [No Abstract]   [Full Text] [Related]  

  • 26. [Clinical assessment of metabolic effects of antihypertensive therapy].
    Tkacheva ON; Shumbutova AIu; Novikova IM; Samsonenko NS; Guseva KIu
    Kardiologiia; 2008; 48(3):34-8. PubMed ID: 18429754
    [No Abstract]   [Full Text] [Related]  

  • 27. [Prevalence of hypertension among young people and efficacy of its treatment with enalapril].
    Bazina IB
    Kardiologiia; 2002; 42(5):23-5. PubMed ID: 12494143
    [No Abstract]   [Full Text] [Related]  

  • 28. [Open trial using ACE inhibitor. Left ventricular hypertrophy diminishes].
    Arend U; Albrecht S; Meisel E; Schmidt J
    MMW Fortschr Med; 2002 Nov; 144(48):51. PubMed ID: 12532545
    [No Abstract]   [Full Text] [Related]  

  • 29. [Experience and comparison of antihypertensive effect of ace inhibitor spirapril and calcium antagonist amlodipinein standard and chronotherapeutic prescription mode].
    Ovchan HO; Khomenko VM; Andrushko II; Ostapchuk OI; Kyrychenko LM
    Wiad Lek; 2017; 70(4):721-724. PubMed ID: 29064793
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Late escape from the antiproteinuric effect of ace inhibitors in nondiabetic renal disease.
    Shiigai T; Shichiri M
    Am J Kidney Dis; 2001 Mar; 37(3):477-83. PubMed ID: 11228170
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficacy and variability of the antiproteinuric effect of ACE inhibition by lisinopril.
    Heeg JE; de Jong PE; van der Hem GK; de Zeeuw D
    Kidney Int; 1989 Aug; 36(2):272-9. PubMed ID: 2550696
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Mechanism of the antiproteinuric effect of angiotensin-converting enzyme inhibition.
    de Zeeuw D; Heeg JE; Stelwagen T; de Jong RJ; de Jong PE
    Contrib Nephrol; 1990; 83():160-5. PubMed ID: 1966072
    [No Abstract]   [Full Text] [Related]  

  • 33. The blunting of the antiproteinuric efficacy of ACE inhibition by high sodium intake can be restored by hydrochlorothiazide.
    Buter H; Hemmelder MH; Navis G; de Jong PE; de Zeeuw D
    Nephrol Dial Transplant; 1998 Jul; 13(7):1682-5. PubMed ID: 9681711
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Antiproteinuric effects of enalapril and losartan: a pilot study.
    White CT; Macpherson CF; Hurley RM; Matsell DG
    Pediatr Nephrol; 2003 Oct; 18(10):1038-43. PubMed ID: 12920631
    [TBL] [Abstract][Full Text] [Related]  

  • 35. High dose enalapril impairs the response to erythropoietin treatment in haemodialysis patients.
    Albitar S; Genin R; Fen-Chong M; Serveaux MO; Bourgeon B
    Nephrol Dial Transplant; 1998 May; 13(5):1206-10. PubMed ID: 9623555
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Do ACE inhibitors influence the dose of human recombinant erythropoietin in dialysis patients?
    Hess E; Sperschneider H; Stein G
    Nephrol Dial Transplant; 1996 Apr; 11(4):749-751. PubMed ID: 8671881
    [No Abstract]   [Full Text] [Related]  

  • 37. [Is it feasible to improve the duration and the efficiency of Ramipril anti-proteinuric response?].
    Simeoni M; Cianfrone P; Comi N; Gentile I; Fabiano FF; Piraina V; Talarico R; Lucisano G; Rivoli L; Andreucci M; Fuiano L; Foti D; Gulletta E; Fuiano G
    G Ital Nefrol; 2015; 32(1):. PubMed ID: 25774586
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [The role of depressive disorders in hypertensive disease and possibilities of their correction: assessment of the effect of tianeptine].
    Kirichenko AA; Ebzeeva EIu
    Kardiologiia; 2002; 42(10):36-40. PubMed ID: 12494055
    [No Abstract]   [Full Text] [Related]  

  • 39. Role of patient factors in therapy resistance to antiproteinuric intervention in nondiabetic and diabetic nephropathy.
    Bos H; Andersen S; Rossing P; De Zeeuw D; Parving HH; De Jong PE; Navis G
    Kidney Int Suppl; 2000 Apr; 75():S32-7. PubMed ID: 10828759
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Different effects between antihypertensive drugs on nephrotic-range proteinuria in renovascular hypertension.
    Ishimitsu T; Yagi H; Ohkubo M; Nakamura Y; Yagi S
    Am J Nephrol; 1994; 14(1):60-3. PubMed ID: 7912475
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.